(1) Bednarski, P. J., Mackay, F. S., and Sadler, P. (2007) Photoactivatable platinum complexes.
Anti-Cancer Agents Med. Chem. 7, 75-93.
(2) Mackay, F. S., Woods, J. A., Heringova, P., Kasparkova, J., Pizarro, A. M., Moggach, S. A.,
Parsons, S., Brabec, V., and Sadler, P. J. (2007) A potent cytotoxic photoactivated platinum complex.
Proc. Natl. Acad. Sci. USA 104, 20743-20748.
(3) Farrer, N. J., Woods, J. A., Salassa, L., Zhao, Y., Robinson, K. S., Clarkson, G. J., Mackay, F.
S., and Sadler, P. J. (2010) A potent trans-diimine platinum anticancer complex photoactivated by
visible light. Angew. Chem. Int. Ed. 49, 1-5.
(4) Kasparkova, J., Novakova, O., Najajreh, Y., Gibson, D., Perez, J.-M., and Brabec, V. (2003)
Effects of a piperidine ligand on the mechanism of action of antitumor cisplatin. Chem. Res. Toxicol. 16,
1424-1432.
(5) Kasparkova, J., Marini, V., Najajreh, Y., Gibson, D., and Brabec, V. (2003) DNA binding
mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing
piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell
lines. Biochemistry 42, 6321-6332.
(6) Kasparkova, J., Novakova, O., Marini, V., Najajreh, Y., Gibson, D., Perez, J.-M., and Brabec,
V. (2003) Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine
ligand: Mechanistic studies on antitumor action. J. Biol. Chem. 278, 47516-47525.
(7) Najajreh, Y., Khazanov, E., Jawbry, S., Ardeli-Tzaraf, Y., Perez, J. M., Kasparkova, J., Brabec,
V., Barenholz, Y., and Gibson, D. (2006) Cationic nonsymmetric transplatinum complexes with
piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and
anticancer efficacy studies. J. Med. Chem. 49, 4665-4673.
(8) Najajreh, Y., Ardeli-Tzaraf, Y., Kasparkova, J., Heringova, P., Prilutski, D., Balter, L., Jawbry,
S., Khazanov, E., Perez, J. M., Barenholz, Y., Brabec, V., and Gibson, D. (2006) Interactions of
platinum complexes containing cationic, bicyclic, nonplanar piperidinopiperidine ligands with
biological nucleophiles. J. Med. Chem. 49, 4674-4683.
(9) Najajreh, Y., Kasparkova, J., Marini, V., Gibson, D., and Brabec, V. (2005) Structural
characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and
one nonplanar heterocyclic amine ligand. J. Biol. Inorg. Chem. 10, 722-731.
(10) Najajreh, Y., Prilutski, D., Ardeli-Tzaraf, Y., Perez, J.-M., Khazanov, E., Barenholz, Y.,
Kasparkova, J., Brabec, V., and Gibson, D. (2005) Structure and unique interactions with DNA of a
cationic trans-platinum complex with the nonplanar bicyclic piperidinopiperidine ligand. Angew. Chem.
Int. Ed. 44, 2-4.
(11) Aris, S. M., and Farrell, N. P. (2009) Towards antitumor active trans-platinum compounds.
Eur. J. Inorg. Chem. 2009, 1293-1302.
(12) Aris, S. M., Knott, K. M., Yang, X., Gewirtz, D. A., and Farrell, N. P. (2009) Modulation of
transplanaramine platinum complex reactivity by systematic modification of carrier and leaving groups.
Inorg. Chim. Acta 362, 929-934.
(13) Zakovska, A., Novakova, O., Balcarova, Z., Bierbach, U., Farrell, N., and Brabec, V. (1998)
DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. Eur. J. Biochem. 254, 547-557.
(14) Brabec, V., Neplechova, K., Kasparkova, J., and Farrell, N. (2000) Steric control of DNA
interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving
groups. J. Biol. Inorg. Chem. 5, 364-368.
(15) Kasparkova, J., Novakova, O., Farrell, N., and Brabec, V. (2003) DNA binding by antitumor
trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional
adducts. Biochemistry 42, 792-800.
(16) Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M.,
and Reedijk, J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA:
Formation, identification, and quantitation. Biochemistry 24, 707-713.
(17) Jamieson, E. R., Jacobson, M. P., Barnes, C. M., Chow, C. S., and Lippard, S. J. (1999)
Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B. J.
Biol. Chem. 274, 12346-12354.
(18) Comess, K. M., Burstyn, J. N., Essigmann, J. M., and Lippard, S. J. (1992) Replication
inhibition and translesion synthesis on templates containing site-specifically placed cisdiamminedichloroplatinum(
II) DNA adducts. Biochemistry 31, 3975-3990.
(19) Pillaire, M. J., Hoffmann, J. S., Defais, M., and Villani, G. (1995) Replication of DNA
containing cisplatin lesions and its mutagenic consequences. Biochimie 77, 803-807.
(20) Damsma, G. E., Alt, A., Brueckner, F., Carell, T., and Cramer, P. (2007) Mechanism of
transcriptional stalling at cisplatin-damaged DNA. Nature Struct. Mol. Biol. 14, 1127-1133.
(21) Todd, R. C., and Lippard, S. J. (2009) Inhibition of transcription by platinum antitumor
compounds. Metallomics 1, 280-291.
(22) Fuertes, M. A., Castilla, J., Alonso, C., and Perez, J. M. (2003) Cisplatin biochemical
mechanism of action: From cytotoxicity to induction of cell death through interconnections between
apoptotic and necrotic pathways. Curr. Med. Chem. 10, 257-266.
(23) Brabec, V., and Palecek, E. (1976) Interaction of nucleic acids with electrically charged
surfaces. II. Conformational changes in double-helical polynucleotides. Biophys. Chem. 4, 76-92.
(24) Brabec, V., and Palecek, E. (1970) The influence of salts and pH on polarographic currents
produced by denatured DNA. Biophysik 6, 290-300.
(25) Keck, M. V., and Lippard, S. J. (1992) Unwinding of supercoiled DNA by platinum ethidium
and related complexes. J. Am. Chem. Soc. 114, 3386-3390.
(26) Brabec, V., and Leng, M. (1993) DNA interstrand cross-links of transdiamminedichloroplatinum(
II) are preferentially formed between guanine and complementary cytosine
residues. Proc. Natl. Acad. Sci. USA 90, 5345-5349.
(27) Lemaire, M. A., Schwartz, A., Rahmouni, A. R., and Leng, M. (1991) Interstrand cross-links
are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II)
and DNA. Proc. Natl. Acad. Sci. USA 88, 1982-1985.
(28) Butour, J. L., and Macquet, J. P. (1977) Differentiation of DNA - platinum complexes by
fluorescence. The use of an intercalating dye as a probe. Eur. J. Biochem. 78, 455-463.
(29) Butour, J. L., Alvinerie, P., Souchard, J. P., Colson, P., Houssier, C., and Johnson, N. P. (1991)
Effect of the amine nonleaving group on the structure and stability of DNA complexes with cis-[Pt(RNH2)
2(NO3)2]. Eur. J. Biochem. 202, 975-980.
(30) Topal, M. D., and Fresco, J. R. (1980) Fluorescence of terbium ion-nucleic acid complexes: A
sensitive specific probe for unpaired residues in nucleic acids. Biochemistry 19, 5531-5537.
(31) Balcarova, Z., and Brabec, V. (1989) Reinterpretation of fluorescence of terbium ion - DNA
complexes. Biophys. Chem. 33, 55-61.
(32) Arquilla, M., Thompson, L. M., Pearlman, L. F., and Simpkins, H. (1983) Effect of platinum
antitumor agents on DNA and RNA investigated by terbium fluorescence. Cancer Res. 43, 1211-1216.
(33) Kasparkova, J., Mellish, K. J., Qu, Y., Brabec, V., and Farrell, N. (1996) Site-specific d(GpG)
intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies.
Biochemistry 35, 16705-16713.
(34) Brabec, V. (2002) DNA modifications by antitumor platinum and ruthenium compounds: their
recognition and repair. Prog. Nucleic Acid Res. Mol. Biol. 71, 1-68.
(35) Bancroft, D. P., Lepre, C. A., and Lippard, S. J. (1990) 195Pt NMR kinetic and mechanistic
studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA. J.
Am. Chem. Soc. 112, 6860-6871.
(36) Brabec, V., Kleinwächter, V., Butour, J. L., and Johnson, N. P. (1990) Biophysical studies of
the modification of DNA by antitumour platinum coordination complexes. Biophys. Chem. 35, 129-141.
(37) Eastman, A., and Barry, M. A. (1987) Interaction of trans-diamminedichloroplatinum(II) with
DNA: Formation of monofunctional adducts and their reaction with glutathione. Biochemistry 26, 3303-
3307.
(38) Prokop, R., Kasparkova, J., Novakova, O., Marini, V., Pizarro, A. M., Navarro-Ranninger, C.,
and Brabec, V. (2004) DNA interactions of new antitumor platinum complexes with trans geometry
activated by a 2-metylbutylamine or sec-butylamine ligand. Biochem. Pharmacol. 67, 1097-1109.
(39) Kasparkova, J., Vojtiskova, M., Natile, G., and Brabec, V. (2008) Unique properties of DNA
interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem.
Eur. J. 14, 1330-1341.
(40) Zerzankova, L., Suchankova, T., Vrana, O., Farrell, N. P., Brabec, V., and Kasparkova, J.
(2010) Conformation and recognition of DNA modified by a new antitumor dinuclear PtII complex
resistant to decomposition by sulfur nucleophiles. Biochem. Pharmacol. 79, 112-121.
(41) Cullinane, C., Mazur, S. J., Essigmann, J. M., Phillips, D. R., and Bohr, V. A. (1999) Inhibition
of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 38,
6204-6212.
(42) Bagchi, M. K., Tsai, S. Y., Weigel, N. L., Tsai, M. J., and O'Malley, B. W. (1990) Regulation
of in vitro transcription by progesterone receptor. Characterization and kinetic studies. J. Biol. Chem.
265, 5129-5134.
(43) Johnson, N. P., Butour, J.-L., Villani, G., Wimmer, F. L., Defais, M., Pierson, V., and Brabec,
V. (1989) Metal antitumor compounds: The mechanism of action of platinum complexes. Prog. Clin.
Biochem. Med. 10, 1-24.
(44) Jamieson, E. R., and Lippard, S. J. (1999) Structure, recognition, and processing of cisplatin-
DNA adducts. Chem. Rev. 99, 2467-2498.
(45) Wang, D., and Lippard, S. J. (2005) Cellular processing of platinum anticancer drugs. Nature
Rev. Drug Discov. 4, 307-320.
(46) Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nature Rev.
Cancer 7, 573-584.
(47) Stehliková, K., Kasparkova, J., Novakova, O., Martinez, A., Moreno, V., and Brabec, V. (2006)
Recognition of DNA modified by trans-[PtCl2NH3(4-hydroxymethylpyridine)] by tumor suppressor
protein p53 and character of DNA adducts of this cytotoxic complex. FEBS J. 273, 301-314.
(48) Brabec, V., Kasparkova, J., Vrana, O., Novakova, O., Cox, J. W., Qu, Y., and Farrell, N.
(1999) DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent.
Biochemistry 38, 6781-6790.
(49) Siddik, Z. H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Oncogene 22, 7265-7279.
(50) Brabec, V., and Kasparkova, J. (2005) Modifications of DNA by platinum complexes:
Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updates 8, 131-146.
(51) Tremeau-Bravard, A., Riedl, T., Egly, J.-M., and Dahmus, M. E. (2003) Fate of RNA
polymerase II stalled at a cisplatin lesion. J. Biol. Chem. 279, 7751-7759.
(52) Tornaletti, S., Patrick, S. M., Turchi, J. J., and Hanawalt, P. C. (2003) Behavior of T7 RNA
polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA.
J. Biol. Chem. 278, 35791-35797.
(53) Jung, Y., and Lippard, S. J. (2007) Direct cellular responses to platinum-induced DNA damage.
Chem. Rev. 107, 1387-1407.
(54) Lovejoy, K. S., Todd, R. C., Zhang, S. Z., McCormick, M. S., D'Aquino, J. A., Reardon, J. T.,
Sancar, A., Giacomini, K. M., and Lippard, S. J. (2008) cis-diammine(pyridine)chloroplatinum(II), a
monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc. Natl.
Acad. Sci. USA 105, 8902-8907.
(55) Lee, K. B., Wang, D., Lippard, S. J., and Sharp, P. A. (2002) Transcription-coupled and DNA
damage dependent ubiquitination of RNA polymerase II in vitro. Proc. Natl. Acad. Sci. U.S.A. 99, 4239-
4244.
(56) Garner, M. M., and Burg, M. B. (1994) Macromolecular crowding and confinement in cells
exposed to hypertonicity. Am. J. Physiol. 266, C877-C892.
(57) Zhai, X. Q., Beckmann, H., Jantzen, H. M., and Essigmann, J. M. (1998) Cisplatin-DNA
adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding
factor. Biochemistry 37, 16307-16315.
(58) Ise, T., Nagatani, G., Imamura, T., Kato, K., Takano, H., Nomoto, M., Izumi, H., Ohmori, H.,
Okamoto, T., Ohga, T., Uchiumi, T., Kuwano, M., and Kohno, K. (1999) Transcription factor Y-box
binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell
nuclear antigen. Cancer Res. 59, 342-346.
(59) Stehlikova, K., Kostrhunova, H., Kasparkova, J., and Brabec, V. (2002) DNA bending and
unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cisdiamminedichloroplatinum(
II) are flanking-base independent. Nucleic Acids Res. 30, 2894-2898.
(60) Donahue, B. A., Augot, M., Bellon, S. F., Treiber, D. K., Toney, J. H., Lippard, S. J., and
Essigmann, J. M. (1990) Characterization of a DNA damage-recognition protein from mammalian cells
that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.
Biochemistry 29, 5872-5880.
(61) Pil, P. M., and Lippard, S. J. (1992) Specific binding of chromosomal protein-HMG1 to DNA
damaged by the anticancer drug cisplatin. Science 256, 234-237.
(62) Kasparkova, J., and Brabec, V. (1995) Recognition of DNA interstrand cross-links of cisdiamminedichloroplatinum(
II) and its trans isomer by DNA- binding proteins. Biochemistry 34, 12379-
12387.
(63) Jung, Y., and Lippard, S. J. (2006) RNA polymerase II blockage by cisplatin-damaged DNA -
Stability and polyubiquitylation of stalled polymerase. J. Biol. Chem. 281, 1361-1370.
(64) Eastman, A. (1987) The formation, isolation and characterization of DNA adducts produced by
anticancer platinum complexes. Pharm. Ther. 34, 155-166.